Long-term Smoking Mediated Down-regulation of Smad3 Induces Resistance to Carboplatin in Non-Small Cell Lung Cancer

Long-term Smoking Mediated Down-regulation of Smad3 Induces Resistance to Carboplatin in Non-Small Cell Lung Cancer

While numerous cell signaling pathways are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the Smad-dependent transforming growth factor β pathway on the therapeutic outcome. Previous reports suggested that patients with lung cancer who conti...

Full description

Bibliographic Details
Main Authors:	Debangshu Samanta, Jacob Kaufman, David P. Carbone, Pran K. Datta
Format:	Article
Language:	English
Published:	Elsevier 2012-07-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558612800984

Similar Items

MiR-216b/Smad3/BCL-2 Axis Is Involved in Smoking-Mediated Drug Resistance in Non-Small Cell Lung Cancer
by: Trung Vu, et al.
Published: (2020-07-01)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
by: Rei Kamitani, et al.
Published: (2022-11-01)

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
by: Reyes Bernabé, et al.
Published: (2024-01-01)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
by: Ding Q, et al.
Published: (2013-08-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Small-cell neuroendocrine tumor of the bladder: Unexpected long-term survival with carboplatin-etoposide therapy in a patient with metastatic stage disease
by: Eduardo J García Rico, et al.
Published: (2023-01-01)

Efficacy Comparison Between Weekly and Triweekly Regimens of Carboplatin-paclitaxel in Non-small Cell Lung Cancer
by: Serdar ATA, et al.
Published: (2023-09-01)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
by: Corey J. Langer, et al.
Published: (2021-01-01)

Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer
by: Mario Eandi
Published: (2006-09-01)

Perftoran® Inhibits Hypoxia-Associated Resistance in Lung Cancer Cells to Carboplatin
by: Amira M. Gamal-Eldeen, et al.
Published: (2022-03-01)

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
by: Eric S Kim, et al.
Published: (2017-01-01)

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer
by: Shashank Sama, et al.
Published: (2023-01-01)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
by: Ayako Shiono, et al.
Published: (2023-01-01)

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel
by: Camila Uanne Resende Avelino, et al.
Published: (2015-04-01)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
by: Shiyu Jiang, et al.
Published: (2021-12-01)

Relationship between Expression of TGF-β1, Smad2, Smad4 and Prognosis  of Patients with Resected Non-small Cell Lung Cancer
by: Mian XIE, et al.
Published: (2015-09-01)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
by: Toshinobu Hayashi, et al.
Published: (2021-01-01)

Long-term effects of tabacco smoking on lung cancer mortality in Poland based on a geographical term
by: Klaudia Barańska, et al.
Published: (2023-04-01)

Evaluation of the LTBP1 and Smad6 Genes Expression in Lung Tissue of Sulfur Mustard-exposed Individuals with Long-term Pulmonary Complications
by: Somaye Mami, et al.
Published: (2019-10-01)

Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
by: PLOS Staff
Published: (2018-01-01)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
by: Minami Seigo, et al.
Published: (2013-01-01)

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
by: Mudad R, et al.
Published: (2017-10-01)

Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin
by: Helena Branco, et al.
Published: (2022-03-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
by: Soo Han Kim, et al.
Published: (2023-03-01)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
by: Treat Joseph, et al.
Published: (2011-02-01)

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.
by: Vítězslav Kolek, et al.
Published: (2017-01-01)

Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin
by: Hala Mohamed El-Shenshawy, et al.
Published: (2012-10-01)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
by: Tobias Dechow, et al.
Published: (2021-11-01)

Short- and Long-Term Impact of Smoking Donors in Lung Transplantation: Clinical and Pathological Analysis
by: Marco Schiavon, et al.
Published: (2021-05-01)

Effect of progesterone on Smad signaling and TGF-β/Smad-regulated genes in lung epithelial cells.
by: Steffen Kunzmann, et al.
Published: (2018-01-01)

Carboplatin-Induced Hypersensitivity Reaction
by: Evangelos Potolidis, et al.
Published: (2012-03-01)

Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma
by: Jeff Yat-Fai Chung, et al.
Published: (2023-03-01)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
by: Sevgi Ayhan, et al.
Published: (2023-09-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Long‐term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane
by: Yuki Kobayakawa, et al.
Published: (2022-07-01)

Top-down in the long term in Crohn's disease
by: Boyapati, R, et al.
Published: (2018)